Egle Therapeutics Strengthens its Executive Leadership Team With the Appointment of Christophe Quéva, Ph.D., as Chief Executive Officer
Egle Therapeutics, a clinical-stage biotechnology company advancing the next generation of regulatory T cell (Treg)-focused therapies for oncology and autoimmune diseases, today announced the appointment of experienced biotechnology industry executive, Christophe Quéva, Ph.D., as Chief Executive Officer (CEO). With over 20 years of experience in the biotechnology industry, Dr. Quéva brings a wealth of expertise as Egle transitions into the clinic its two lead drug candidates, EGL-001 and EGL-003.
“I am thrilled to join Egle Therapeutics and collaborate with a team renowned for its deep scientific expertise in regulatory T cells and its strong track record in developing innovative drug candidates for immunology and oncology,” said Christophe Quéva, Ph.D. “Egle is uniquely positioned to demonstrate the therapeutic potential of harnessing regulatory T cells for treating both cancer and autoimmune diseases.”
“As we transition from a company with preclinical assets to a fully-fledged clinical-stage biotech, we will benefit greatly from Christophe's deep operational and strategic expertise. We are delighted to welcome Christophe to the Egle team and look forward to the successes he will drive,” said Vincent Brichard, M.D., Egle’s Interim CEO and Board member.
“Christophe’s appointment marks a pivotal moment for Egle, as we focus on clinical development and advancing our technology platform, his experience, knowledge and networks of the sector will ensure Egle continues to shape its future," said Michel Detheux, Chairman of the board.
Christophe Quéva, Ph.D.
Dr. Christophe Quéva brings over two decades of experience in immuno-oncology, spanning portfolio development from target identification to clinical trials and regulatory approvals. Before joining Egle, he founded and led Ovie Therapeutics, a company focused on an innovative treatment for brain cancer. Since 2022, he has also served as Chief Scientific Officer at DEM BioPharma, driving the development of cancer macrophage-targeting therapies. Prior to this, Dr. Quéva was Chief Scientific Officer at Oncorus, where he advanced next-generation immunotherapies using oncolytic viruses and RNA therapeutics. He also held the same role at iTeos Therapeutics, overseeing the development of a groundbreaking immuno-oncology portfolio.
Earlier in his career, Dr. Quéva held leadership roles at Gilead Sciences, Amgen, and AstraZeneca, contributing to oncology and inflammation drug discovery. He holds a Ph.D. in Life and Health Sciences from the University of Lille in France and completed postdoctoral research in cancer biology at the Fred Hutchinson Cancer Research Center. Dr. Quéva’s extensive career includes numerous patents and publications in the oncology field, reflecting his commitment to advancing patient care through innovative science and leadership.
About Egle Therapeutics SAS (Egle)
Egle Therapeutics is a biotechnology company focused on developing immunotherapies targeting suppressive regulatory T cells. Egle is leveraging a proprietary discovery platform to unveil novel Treg specific targets and to develop innovative Treg-focused drug candidates for oncology and autoimmune diseases. Egle is evaluating its most advanced drug candidate in oncology, EGL-001 (a Treg-selective anti-CTLA4-IL-2m), in a Phase I/II clinical trial. In autoimmunity, Egle has completed IND-enabling studies for, EGL-003 (an IL-2 Treg engager), and is poised to commence a clinical trial in 2025.
Find out more at www.egle-tx.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250113580621/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bynder Showcases Its New and Expanded AI Capabilities at NRF to Help Retailers Drive Personalized Content Experiences13.1.2025 12:24:00 CET | Press release
Bynder, a global leader in AI-powered enterprise DAM, is showcasing its latest AI innovations at the NRF retail show in New York. These new innovations build on the company’s already extensive set of AI capabilities, to help power global brands to drive personalized content experiences. During the show, Bynder revealed its Natural Language Search functionality which will help DAM users find images quickly by simply describing them in all major languages. Bynder already has more than 500 customers leveraging its existing AI Search capabilities such as similarity search, text in image and facial recognition. In addition to this, Bynder launched its next generation Duplicate Image Finder which helps organize and maintain a brand’s DAM by detecting and removing duplicate images at the touch of a button. This enhanced feature is now AI assisted to detect exact duplicate images with greater accuracy and allow administrators to easily delete them from the DAM. For retailers that include video
Cytovance Biologics and PolyPeptide Announce Collaboration for Microbial and Mammalian-Expressed Peptide Drugs13.1.2025 12:15:00 CET | Press release
This collaboration offers an integrated solution for customers seeking to outsource the development and manufacturing of microbial and mammalian-expressed peptide drugs, with scalable options that address the full range of product requirements. In response to the growing demand for peptide drugs, Cytovance Biologics and PolyPeptide have announced a partnership that combines Cytovance’s expertise in microbial and mammalian expression, process development and cGMP manufacturing with PolyPeptide’s capabilities in complex peptide development and manufacturing. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250113598664/en/ Axel Schleyer, CCO of Cytovance Biologics: “Cytovance has been supporting the development and scale-up of microbial and mammalian-expressed biologics for two decades. Combining our strengths with PolyPeptide’s is exactly what our customers and the industry need to support the rapidly advancing market demand.”
Transition Industries and Veolia Partner to Redefine Industrial Water Use at the Pacifico Mexinol Project in Mexico13.1.2025 09:24:00 CET | Press release
Transition Industries LLC, a developer of world-scale, net-zero carbon emissions methanol and hydrogen projects, and Veolia Water Technologies & Solutions, world leader in water technology, have signed an agreement to explore the provision of advanced industrial water technology for the Pacifico Mexinol project in Sinaloa, Mexico. Expected to initiate operations in 2028, Pacifico Mexinol is poised to be the world’s largest standalone ultra-low carbon chemical production facility in the world, with an output of 6,145 metric tons of methanol (MT) per day. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250112655528/en/ The memorandum of understanding (MOU) outlines the collaboration between Transition Industries and Veolia to develop a purpose-driven water strategy for the Pacifico Mexinol project. Designed with Ahome Municipality’s Drinking Water and Sewage Board (JAPAMA), this strategy would make the Pacifico Mexinol site one
Avanzanite Bioscience Announces Appointment of Chief Technical Officer to Accelerate European Expansion and Drive Growth13.1.2025 07:00:00 CET | Press release
Appointment of Jason Cameron as first Chief Technical Officer underscores Avanzanite’s strategic commitment to accelerating revenue growth and expanding its footprint across Europe and beyond. With over 25 years of global pharmaceutical experience, Cameron is poised to enhance Avanzanite’s commercial distribution of orphan medicines and fuel the company’s ambitious growth trajectory. In the short term, Cameron will focus on deepening Avanzanite’s presence in 26 European countries and spearheading the execution of strategic partnerships slated for 2025. Avanzanite Bioscience B.V., a leading commercial-stage specialty pharmaceutical company committed to bringing ground-breaking medicines for rare diseases to market, announced today the appointment of Jason Cameron as Chief Technical Officer (CTO). This move marks a significant step in Avanzanite’s mission to accelerate growth, expand its presence in Europe, and advance the company’s next phase of international partnerships and product la
Dubai Culture Launches ‘Creative Dubai – Navigating Tomorrow’s Creative Landscape’ Report13.1.2025 07:00:00 CET | Press release
Dubai Culture and Arts Authority (Dubai Culture) has launched the ‘Creative Dubai: Navigating Tomorrow’s Creative Landscape’ report developed in collaboration with DinarStandard, a privately owned growth strategy research and advisory firm empowering organisations for responsible global impact. The report highlights Dubai’s achievements in the cultural and creative industries, the key factors contributing to the city’s cultural vision, and significant data tracking the sector’s transformation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250112169940/en/ Key Highlights of Creative Economy Figures and FDI in Dubai’s Cultural and Creative Industries (Graphic: AETOSWire) The report provides a comprehensive overview of the creative sector, which serves as a significant global economic force, representing 6.1% of the global economy with a total value of US$4.3 trillion. The report also shows that the UAE has the largest creativ
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom